Page last updated: 2024-08-23

cabergoline and pergolide

cabergoline has been researched along with pergolide in 60 studies

Research

Studies (60)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (8.33)	18.2507
2000's	41 (68.33)	29.6817
2010's	12 (20.00)	24.3611
2020's	2 (3.33)	2.80

Authors

Authors	Studies
Audinot, V; Boutin, JA; Cussac, D; Maiofiss, L; Millan, MJ; Newman-Tancredi, A	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Mark, MH; Sage, JI	1
Arai, N; Fukuyama, J; Isaji, M; Kuno, S; Miyata, H; Mizuta, E	1
Arai, N; Isaji, M; Itoh, F; Kojima, M; Miyagi, M; Taya, F; Ujiie, A	1
Conner, P; Fried, G	1
Montastruc, JL; Rascol, O; Senard, JM	1
Brannan, T; Prikhojan, A; Yahr, MD	1
Colao, A; di Sarno, A; di Somma, C; Lombardi, G; Pivonello, R	1
Gekht, AB	1
Bain, PG; Navan, P	1
Clarke, CE; Guttman, M	1
Fujinami, A; Kuno, S; Matsui, H; Mizuta, I; Ohta, K; Ohta, M	1
Bankowski, BJ; Zacur, HA	1
Amad, M; Dunyach, JJ; Hughes, N; Paul, G; Splendore, M; Winnik, W	1
Ball, SG; Hall, K; James, RA; Kendall-Taylor, P; Pearce, SH; Quinton, R; Sibal, L; Ugwu, P	1
Hotta, M; Kamo, T; Kawakami, M; Nemoto, S; Oshima, J; Shimojo, S; Shiraishi, M; Sugihara, H; Takahashi, Y; Yasaki, S	1
Burkhard, PR; Flachsbart, KD; Fross, RD; Horvath, J; Kleiner-Fisman, G; Lang, AE; Lerch, R; Liaudat, S; Pache, JC; Rakowski, H; Raskoff, WJ; Stalder, H	1
Grosset, D; Grosset, K; Macphee, G; Needleman, F	1
Baran, AS; Rack, MJ; Richert, AC; Roffwarg, HP	1
Basu, S; Chaudhuri, KR; Dhawan, V; Jackson, G; Odin, P	1
Goetz, CG; Poewe, W; Rascol, O; Sampaio, C	1
Abs, R; Verhelst, J	1
Molitch, ME	1
Boulos, PT; Hamilton, DK; Laws, ER; Vance, ML	1
Burger, E; Härtter, S; Kvernmo, T	1
Fuhrmann, JT; Junghanns, S; Koch, R; Oelwein, C; Reichmann, H; Simonis, G; Storch, A; Strasser, RH	1
Roth, BL	1
Andersohn, F; Garbe, E; Haverkamp, W; Schade, R; Suissa, S	1
Antonini, A; Gatto, G; Gentile, R; Pezzoli, G; Tesei, S; Zanettini, R	2
Erginöz, E; Kenangil, G; Koldas, L; Ozekmekçi, S; Sahin, T	1
Altschuler, EL; Kast, RE	1
Senol, MG; Togrol, RE	1
Fuhrmann, JT; Simonis, G; Strasser, RH	1
Antonini, A; Poewe, W	1
Arcoraci, V; Morgante, L; Savica, R; Tari, M; Trifirò, G	1
Daida, H; Hatano, T; Hattori, N; Iwama, Y; Komine-Kobayashi, M; Mizuno, Y; Mochizuki, H; Nakayama, T; Sakai, M; Urabe, T; Yamashiro, K	1
Doi, K; Isono, T; Kawamura, T; Kitagawa, N; Kuno, S; Masaki, M; Mizuta, E; Oeda, T; Sawada, H; Taniguchi, S; Yaku, H; Yamamoto, K; Yutani, C	1
Andersohn, F; Garbe, E	1
Sherlock, M; Steeds, R; Toogood, AA	1
Fujioka, S; Iwamoto, K; Kawamura, M; Nakajima, M; Ohno, H	1
Pullan, PT	1
Bhattacharyya, S; Davar, J; Mikhailidis, DP; Schapira, AH	1
Hornyak, M; Kohnen, R; Kriston, L; Riemann, D; Scholz, H; Trenkwalder, C	1
Kubota, K; Ooba, N; Yamaguchi, T	1
Ikeda, S; Ishizaki, T; Morikawa, K; Nakaoka, S; Nakayama, T; Satoh, T; Urushihara, H	1
Aurora, RN; Bista, SR; Casey, KR; Kristo, DA; Lamm, CI; Rosenberg, RS; Rowley, JA; Tracy, SL; Zak, RS	1
Alkabbani, A; Doshi, K; Hamrahian, A; Hatipoglu, B; Kennedy, L; Makin, V; Mon, SY; Olansky, L; Thorton, JN; Weil, R	1
Hashida, H; Hattori, N; Iijima, M; Kano, O; Kubo, S; Matsumura, M; Murakami, H; Nanri, K; Okuma, Y; Suzuki, M; Suzuki, Y; Tomimitsu, H; Utsumi, H	1
Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ	1
Ikeda, S; Ishizaki, T; Nakaoka, S; Nakayama, T; Satoh, T; Urushihara, H; Yamamoto, M	1
Bianchini, E; Bramanti, P; Cilia, R; Ciurleo, R; de Luise, C; Di Lorenzo, G; Ilardi, M; Italiano, D; Pezzoli, G; Polimeni, G; Rijnbeek, P; Ross, D; Stocchi, F; Sturkenboom, M; Trifirò, G; Vacca, L; Zanettini, R	1
Jobic, Y; Tribouilloy, C	1
Auriemma, RS; Colao, A; Negri, M; Patalano, R; Pirchio, R; Pivonello, C; Pivonello, R	1
Kasica, N; Mackiewicz, J; Osęka, M; Saładziak, K; Święch, A	1

Reviews

19 review(s) available for cabergoline and pergolide

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Hyperprolactinemia; etiology, diagnosis and treatment alternatives. Acta obstetricia et gynecologica Scandinavica, 1998, Volume: 77, Issue:3 Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pergolide; Prolactin; Receptors, Prolactin	1998
Treatment of Parkinson's disease should begin with a dopamine agonist. Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:5 Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D2; Thiazoles	1999
Dopamine receptor agonists for treating prolactinomas. Expert opinion on investigational drugs, 2002, Volume: 11, Issue:6 Topics: Aminoquinolines; Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Ergot Alkaloids; Female; Humans; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma	2002
DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17 Suppl 4 Topics: Benzophenones; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Nitrophenols; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Tolcapone	2002
[Use of dopamine agonists in the treatment of Parkinson's disease]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2002, Volume: 102, Issue:9 Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Controlled Clinical Trials as Topic; Dopamine Agonists; Ergolines; Humans; Indoles; Lisuride; Parkinson Disease; Pergolide; Piribedil; Placebos; Pramipexole; Serotonin Receptor Agonists; Thiazoles; Time Factors	2002
Dopamine agonist monotherapy in Parkinson's disease. Lancet (London, England), 2002, Nov-30, Volume: 360, Issue:9347 Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon	2002
Dopamine agonist therapy for hyperprolactinemia. Clinical obstetrics and gynecology, 2003, Volume: 46, Issue:2 Topics: Aminoquinolines; Benzothiazoles; Bromocriptine; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Ergoloid Mesylates; Female; Humans; Hyperprolactinemia; Indoles; Pergolide; Pramipexole; Thiazoles	2003
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:5 Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone	2005
Hyperprolactinemia: pathophysiology and management. Treatments in endocrinology, 2003, Volume: 2, Issue:1 Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estrogens; Female; Humans; Hyperprolactinemia; Male; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma; Radiotherapy; Surgical Procedures, Operative	2003
Pharmacologic resistance in prolactinoma patients. Pituitary, 2005, Volume: 8, Issue:1 Topics: Bromocriptine; Cabergoline; Cell Proliferation; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Resistance; Ergolines; Estrogens; Female; Humans; Male; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Dopamine D2	2005
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clinical therapeutics, 2006, Volume: 28, Issue:8 Topics: Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Heart Valve Diseases; Humans; Indoles; Pergolide; Pulmonary Fibrosis; Receptors, Dopamine	2006
Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists. Movement disorders : official journal of the Movement Disorder Society, 2007, Oct-15, Volume: 22, Issue:13 Topics: Antiparkinson Agents; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Drug Combinations; Echocardiography; Ergolines; Ergot Alkaloids; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide; Product Surveillance, Postmarketing	2007
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. The Lancet. Neurology, 2007, Volume: 6, Issue:9 Topics: Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide	2007
Drug-induced fibrotic valvular heart disease. Lancet (London, England), 2009, Aug-15, Volume: 374, Issue:9689 Topics: Antiparkinson Agents; Appetite Depressants; Cabergoline; Dexfenfluramine; Dopamine Agonists; Drug Monitoring; Ergolines; Ergotamine; Fenfluramine; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Methysergide; Migraine Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Patient Selection; Pergolide; Receptors, Serotonin; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins; Vasoconstrictor Agents	2009
Dopamine agonists for restless legs syndrome. The Cochrane database of systematic reviews, 2011, Mar-16, Issue:3 Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Humans; Levodopa; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Restless Legs Syndrome; Severity of Illness Index	2011
The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep, 2012, Aug-01, Volume: 35, Issue:8 Topics: Academies and Institutes; Benzothiazoles; Cabergoline; Carbamates; Dopamine Agents; Ergolines; Evidence-Based Medicine; gamma-Aminobutyric Acid; Humans; Indoles; Levodopa; Nocturnal Myoclonus Syndrome; Pergolide; Peripheral Nervous System Diseases; Pramipexole; Restless Legs Syndrome; Sleep Medicine Specialty; United States; Venous Insufficiency	2012
Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:7 Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline	2013
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms. Frontiers in endocrinology, 2021, Volume: 12 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aminoquinolines; beta-Arrestins; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Filamins; Growth Hormone-Secreting Pituitary Adenoma; Humans; Lisuride; MicroRNAs; Pergolide; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2	2021

Trials

5 trial(s) available for cabergoline and pergolide

Article	Year
Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary, 2002, Volume: 5, Issue:4 Topics: Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Follicle Stimulating Hormone; Humans; Hypopituitarism; Luteinizing Hormone; Male; Middle Aged; Pergolide; Pituitary Function Tests; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone; Thyrotropin	2002
Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2004, Volume: 111, Issue:6 Topics: Aged; Antiparkinson Agents; Bromocriptine; Cabergoline; Ergolines; Humans; Parkinson Disease; Pergolide; Prospective Studies; Treatment Outcome	2004
Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Movement disorders : official journal of the Movement Disorder Society, 2007, Jan-15, Volume: 22, Issue:2 Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Echocardiography; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Hypertrophy, Left Ventricular; Indoles; Male; Middle Aged; Mitral Valve Insufficiency; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Tricuspid Valve Insufficiency	2007
Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2009, Volume: 16, Issue:6 Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Humans; Japan; Outcome Assessment, Health Care; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Time Factors; Treatment Outcome	2009
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease. Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:3 Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3	2013

Other Studies

36 other study(ies) available for cabergoline and pergolide

Article	Year
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:2 Topics: Animals; Antiparkinson Agents; Binding Sites; Binding, Competitive; Cholinergic Antagonists; Cloning, Molecular; Cluster Analysis; Dopamine Agonists; Humans; Rats; Receptor, Muscarinic M1; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Histamine H1; Receptors, Muscarinic; Receptors, Neurotransmitter; Receptors, Serotonin	2002
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile. Annals of neurology, 1995, Volume: 37, Issue:1 Topics: Aged; Bromocriptine; Cabergoline; Chorea; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Physiologic; Parkinson Disease; Pergolide; Sweating	1995
Differential effects of three dopamine receptor agonists in MPTP-treated monkeys. Journal of neural transmission. Parkinson's disease and dementia section, 1995, Volume: 10, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Macaca fascicularis; Parkinson Disease, Secondary; Pergolide	1995
Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats. Biological & pharmaceutical bulletin, 1996, Volume: 19, Issue:9 Topics: Animals; Benzazepines; Binding, Competitive; Bromocriptine; Cabergoline; Dopamine Agonists; Dopamine Antagonists; Ergolines; In Vitro Techniques; Male; Pergolide; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Stereotyped Behavior	1996
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats. Journal of neural transmission (Vienna, Austria : 1996), 2000, Volume: 107, Issue:10 Topics: Animals; Benzothiazoles; Brain; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Indoles; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Thiazoles	2000
Long term tolerability of high dose ergoline derived dopamine agonist therapy for the treatment of Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 2002, Volume: 73, Issue:5 Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Drug Tolerance; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Time	2002
Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes. Life sciences, 2003, Jun-20, Volume: 73, Issue:5 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Astrocytes; Blotting, Northern; Brain-Derived Neurotrophic Factor; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Ergolines; Glial Cell Line-Derived Neurotrophic Factor; Mice; Mice, Inbred ICR; Nerve Growth Factor; Nerve Growth Factors; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors	2003
High-sensitivity quantitation of cabergoline and pergolide using a triple-quadrupole mass spectrometer with enhanced mass-resolution capabilities. Journal of mass spectrometry : JMS, 2003, Volume: 38, Issue:7 Topics: Animals; Cabergoline; Cattle; Chromatography, High Pressure Liquid; Dopamine Agonists; Ergolines; Pergolide; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization	2003
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:6 Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agonists; Drug Combinations; Echocardiography, Transesophageal; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Levodopa; Male; Parkinson Disease; Pergolide	2004
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:11 Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Therapeutic Equivalency; Thiazoles	2004
Cardiopulmonary complications of ergot-derivative dopamine agonists. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:10 Topics: Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Pergolide; Pulmonary Fibrosis; Risperidone	2004
Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:12 Topics: Aortic Valve; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Fibrosis; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide	2004
Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary, 2005, Volume: 8, Issue:1 Topics: Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Remission Induction; Retrospective Studies; Treatment Outcome	2005
Drugs and valvular heart disease. The New England journal of medicine, 2007, Jan-04, Volume: 356, Issue:1 Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Pergolide; Receptor, Serotonin, 5-HT2B; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists	2007
Dopamine agonists and the risk of cardiac-valve regurgitation. The New England journal of medicine, 2007, Jan-04, Volume: 356, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Case-Control Studies; Cohort Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Logistic Models; Male; Middle Aged; Parkinson Disease; Pergolide; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists	2007
Valvular heart disease and the use of dopamine agonists for Parkinson's disease. The New England journal of medicine, 2007, Jan-04, Volume: 356, Issue:1 Topics: Aged; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Mitral Valve; Parkinson Disease; Pergolide; Regression Analysis; Risk; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Ultrasonography	2007
Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline. Clinical neurology and neurosurgery, 2007, Volume: 109, Issue:4 Topics: Aged; Antiparkinson Agents; Aortic Valve Insufficiency; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Retrospective Studies; Tricuspid Valve Insufficiency	2007
Parkinson's drugs linked to heart valve trouble. Harvard heart letter : from Harvard Medical School, 2007, Volume: 17, Issue:8 Topics: Antiparkinson Agents; Cabergoline; Ergolines; Heart Valve Diseases; Humans; Pergolide	2007
Dopamine agonists and valvular heart disease. The New England journal of medicine, 2007, Apr-19, Volume: 356, Issue:16 Topics: Antipsychotic Agents; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Methysergide; Pergolide; Receptor, Serotonin, 5-HT2B; Retroperitoneal Fibrosis; Serotonin 5-HT2 Receptor Agonists; Serotonin Antagonists	2007
Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology, 2007, Jul-03, Volume: 69, Issue:1 Topics: Antiparkinson Agents; Benzothiazoles; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Parkinson Disease; Patient Selection; Pergolide; Pramipexole; Research Design; Sex Factors	2007
Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent. Journal of the American Geriatrics Society, 2008, Volume: 56, Issue:2 Topics: Aged; Antiparkinson Agents; Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Female; Humans; Male; Parkinson Disease; Pergolide; Treatment Outcome	2008
The frequency of cardiac valvular regurgitation in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2008, May-15, Volume: 23, Issue:7 Topics: Aged; Aortic Valve Insufficiency; Azepines; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Mitral Valve Insufficiency; Parkinson Disease; Pergolide; Pramipexole; Prevalence	2008
High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2009, Volume: 116, Issue:2 Topics: Age Factors; Aged; Benzothiazoles; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Hypertension; Male; Parkinson Disease; Pergolide; Pramipexole; Risk Factors	2009
Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Movement disorders : official journal of the Movement Disorder Society, 2009, Jan-15, Volume: 24, Issue:1 Topics: Aged; Aged, 80 and over; Apomorphine; Benzothiazoles; Bromocriptine; Cabergoline; Databases, Factual; Dopamine Agonists; Endomyocardial Fibrosis; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Indoles; Male; Middle Aged; Pergolide; Pericarditis; Pleural Diseases; Pramipexole; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Tetrahydronaphthalenes; Thiophenes; United States	2009
Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do. Heart (British Cardiac Society), 2009, Volume: 95, Issue:7 Topics: Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Parkinson Disease; Pergolide; Tricuspid Valve Insufficiency	2009
Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy. Internal medicine journal, 2009, Volume: 39, Issue:4 Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Parkinson Disease; Pergolide; Prolactin; Serotonin 5-HT2 Receptor Agonists; Ultrasonography	2009
Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovascular therapeutics, 2011, Volume: 29, Issue:6 Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Heart Valve Diseases; Humans; Italy; Male; Middle Aged; Parkinson Disease; Patient Selection; Pergolide; Prevalence; Prognosis; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Ultrasonography	2011
The older Parkinson's disease drugs pergolide and cabergoline have been linked to heart problems. Are there any new Parkinson's drugs which are safer for patients with heart risks? Heart advisor, 2009, Volume: 12, Issue:8 Topics: Antiparkinson Agents; Aortic Valve Insufficiency; Cabergoline; Dopamine Agonists; Ergolines; Health Knowledge, Attitudes, Practice; Humans; Parkinson Disease; Pergolide	2009
The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008. Drug safety, 2011, Apr-01, Volume: 34, Issue:4 Topics: Cabergoline; Databases, Factual; Dopamine Agonists; Drug Prescriptions; Drug Utilization Review; Ergolines; Government Regulation; Heart Valve Diseases; Humans; Insurance Claim Review; Japan; Legislation, Drug; Parkinson Disease; Pergolide; Regression Analysis; Ultrasonography	2011
Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease. Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:7 Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Drug Labeling; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Incidence; Japan; Male; Middle Aged; Parkinson Disease; Pergolide; Retrospective Studies; Risk Factors	2011
Risk of thromboembolic events in patients with prolactinomas compared with patients with nonfunctional pituitary adenomas. Pituitary, 2013, Volume: 16, Issue:4 Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Thromboembolism; Young Adult	2013
Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010. PloS one, 2014, Volume: 9, Issue:6 Topics: Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Drug Prescriptions; Ergolines; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide	2014
Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. Journal of neural transmission (Vienna, Austria : 1996), 2015, Volume: 122, Issue:6 Topics: Aged; Antiparkinson Agents; Cabergoline; Cohort Studies; Echocardiography; Ergolines; Female; Guideline Adherence; Heart Valve Diseases; Heart Valves; Humans; Incidence; Italy; Male; Middle Aged; Parkinson Disease; Pergolide; Practice Guidelines as Topic; Prevalence; Retrospective Studies; Risk Factors; Supranuclear Palsy, Progressive	2015
[Drug-induced valve heart disease]. La Revue du praticien, 2016, Volume: 66, Issue:8 Topics: Cabergoline; Dopamine Agonists; Heart Valve Diseases; Humans; Pergolide	2016
The Inhibitory Effect of Selected D Cells, 2022, 04-02, Volume: 11, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Bromocriptine; Cabergoline; Dopamine Agonists; Hypoxia; Larva; Neovascularization, Pathologic; Pergolide; Vascular Endothelial Growth Factor A; Zebrafish	2022